Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia.

Abstract

A 31-year-old woman with Philadelphia chromosome-positive chronic myeloid leukaemia (CML) was treated intermittently with high-dose busulphan over a 6-yr period (total dose 1320 mg). 3 yr later (after receiving no further cytotoxic drugs) she developed pancytopenia and marrow aplasia of relatively abrupt onset. Transfusion of reconstituted blood-derived stem cells (collected 7 yr previously) re-established chronic phase CML. These events are more consistent with 'stem cell exhaustion' than with an acquired marrow microenvironmental defect occurring in the course of CML. The contribution of busulphan is uncertain.

• Authors: S J Bowcock, D A Galton, J M Goldman
• Journal: European journal of haematology (Eur J Haematol) Vol. 42 Issue 5 Pg. 496-7 (May 1989) ISSN: 0902-4441 [Print] England
• PMID: 2567249 (Publication Type: Case Reports, Journal Article)

Chemical References

• Busulfan

Topics

• Adult
• Busulfan (adverse effects, therapeutic use)
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Myelodysplastic Syndromes (chemically induced, therapy)
• Pancytopenia (chemically induced, therapy)
• Time Factors